Jones Hill Capital LP — 13F Holdings & Portfolio
CIK 2102314 · latest 13F-HR filed 2026-08-13
Jones Hill Capital LP manages $470.4M in 13F-reported U.S. long-equity assets across 29 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BMRN (17.42%), GILD (9.21%), ARQT (6.07%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 15 new positions and exited 12; 6 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- RELMADA THERAPEUTICS INC$22.9M +960.3%
- TREVI THERAPEUTICS INC$20.6M +465.6%
- PHARVARIS N V$18.7M +396.8%
- BIOMARIN PHARMACEUTICAL INC$10.3M +14.3%
- TONIX PHARMACEUTICALS HLDG C$1.8M +28.4%
Top Trims
- VERTEX PHARMACEUTICALS INC-$43.0M -88.6%
- ENLIVEN THERAPEUTICS INC-$20.7M -89.1%
- NUVALENT INC-$18.7M -60.6%
- CAPRICOR THERAPEUTICS INC-$17.5M -63.3%
- AMYLYX PHARMACEUTICALS INC-$6.2M -27.7%
New Positions
- GILEAD SCIENCES INC$43.3M
- ARCUTIS BIOTHERAPEUTICS INC$28.6M
- MADRIGAL PHARMACEUTICALS INC$28.2M
- XENON PHARMACEUTICALS INC$22.2M
- IMMUNOCORE HLDGS PLC$16.3M
Exited Positions
- VAXCYTE INC$37.5M
- TERNS PHARMACEUTICALS INC$27.5M
- ULTRAGENYX PHARMACEUTICAL IN$24.4M
- ARGENX SE$19.0M
- FULCRUM THERAPEUTICS INC$13.6M
Jones Hill Capital LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $81.9M | 17.42% | 1,431,590 | SH |
| 2 | GILEAD SCIENCES INC | GILD | 375558103 | $43.3M | 9.21% | 343,043 | SH |
| 3 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $28.6M | 6.07% | 1,089,701 | SH |
| 4 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $28.2M | 6.00% | 52,545 | SH |
| 5 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $26.5M | 5.63% | 892,621 | SH |
| 6 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $25.3M | 5.38% | 3,655,075 | SH |
| 7 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $25.0M | 5.31% | 1,339,212 | SH |
| 8 | PHARVARIS N V | PHVS | N69605108 | $23.4M | 4.98% | 677,879 | SH |
| 9 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $22.2M | 4.72% | 367,900 | SH |
| 10 | ANI PHARMACEUTICALS INC | ANIP | 00182C103 | $19.4M | 4.11% | 233,808 | SH |
| 11 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $16.3M | 3.46% | 512,856 | SH |
| 12 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $16.1M | 3.41% | 894,058 | SH |
| 13 | INSMED INC | INSM | 457669307 | $13.0M | 2.77% | 122,375 | SH |
| 14 | NUVALENT INC | NUVL | 670703107 | $12.2M | 2.58% | 98,442 | SH |
| 15 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $10.1M | 2.15% | 420,751 | SH |
| 16 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $9.3M | 1.98% | 1,759,492 | SH |
| 17 | IMMUNIC INC | IMUX | 4525EP200 | $8.3M | 1.76% | 539,814 | SH |
| 18 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $8.1M | 1.72% | 747,313 | SH |
| 19 | TONIX PHARMACEUTICALS HLDG C | TNXP | 890260839 | $8.0M | 1.70% | 625,428 | SH |
| 20 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $7.4M | 1.58% | 340,000 | SH |
| 21 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $7.2M | 1.53% | 574,166 | SH |
| 22 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $6.7M | 1.43% | 659,213 | SH |
| 23 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $6.1M | 1.30% | 653,572 | SH |
| 24 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $5.6M | 1.18% | 57,100 | SH |
| 25 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $5.5M | 1.17% | 11,123 | SH |
| 26 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $2.5M | 0.54% | 49,850 | SH |
| 27 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $2.2M | 0.46% | 40,567 | SH |
| 28 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $1.8M | 0.37% | 161,486 | SH |
| 29 | ACHIEVE LIFE SCIENCE INC | ACHV | 004468500 | $174.7K | 0.04% | 26,760 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $470.4M | 29 | 0002102314-26-000005 |
| 2026-03-31 | 2026-05-14 | $466.5M | 26 | 0002102314-26-000003 |
EIGHTH FLOOR SOUTH
NEW YORK, NY 10013